Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned an average recommendation of “Hold” from the nine analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $31.8333.

Several research analysts have issued reports on STRO shares. HC Wainwright increased their price objective on Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research note on Monday, December 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target on the stock in a research report on Tuesday, January 20th. Finally, Wedbush reaffirmed a “neutral” rating and set a $100.00 price objective (up previously from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd.

Sutro Biopharma Stock Up 1.0%

Shares of STRO stock opened at $15.10 on Tuesday. The business’s 50 day moving average is $11.39 and its two-hundred day moving average is $9.85. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $21.25. The company has a market cap of $128.50 million, a PE ratio of -0.58 and a beta of 1.54.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.25). The business had revenue of $9.69 million for the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%. As a group, equities analysts expect that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

Several large investors have recently made changes to their positions in STRO. Catalyst Funds Management Pty Ltd bought a new position in Sutro Biopharma during the 2nd quarter worth approximately $27,000. Bridgeway Capital Management LLC raised its holdings in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. Savant Capital LLC bought a new position in shares of Sutro Biopharma during the second quarter worth $37,000. CWM LLC grew its holdings in shares of Sutro Biopharma by 73.2% in the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after buying an additional 23,941 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Sutro Biopharma by 174.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after buying an additional 38,561 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.